# CanBas Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/canbas-co

- Industry: Pharmaceuticals
- Headquarters: Numazu, Japan
- Website: www.canbas.co.jp
- Total disclosed funding: $20M
- Latest round: Series D (Nov 30, 2005)
- Investors on record: 7

## About

CanBas Co., Ltd. is a Japanese biotechnology firm focused on developing innovative cancer therapeutics, particularly in immuno-oncology, aiming to improve treatment outcomes for patients with various types of cancer.CanBas Co., Ltd. is headquartered in Numazu, Japan and specializes in cancer therapeutics development. The company underwent a significant milestone by raising USD 14.8 mn in an IPO on September 17, 2009, securing its position in the oncology sector. Specific details about the founder are not available, and there are no known subsidiaries or parent companies.CanBas Co., Ltd. specializes in the research and development of innovative cancer therapeutics, focusing on immuno-oncology products. Their core offerings include flagship drug candidates CBP501, an immune igniter, and CBS9106, a reversible XPO1 inhibitor, designed to enhance the body’s immune response against tumors. These products are aimed at treating various cancers and are intended for clinical use to improve patient outcomes. CanBas is actively conducting clinical trials to advance these therapies in markets including Japan, North America, and Europe, targeting healthcare professionals and cancer patients.In 2023, CanBas reported a revenue of USD 0.00, with an EBITDA of USD -7,045,367.60. The company generates revenue through strategic partnerships and collaborations, typically involving licensing agreements and co-development arrangements for their drug candidates, which are aligned with the high-value nature of oncology therapeutics, usually involving multi-million dollar agreements tied to drug development milestones.CanBas Co., Ltd. plans to leverage the funds raised in its IPO to support the ongoing development of its drug candidates and expand into new geographical markets, including North America and Europe, by the next few years. The company is focusing on advancing its new products through upcoming clinical trials and aims to establish direct sales to healthcare providers once its products receive regulatory approval, thereby creating a robust income stream from their proprietary cancer therapies.

## Funding rounds

- Series D, Nov 30, 2005, $20M — Mitsui Global Investment, Nomura Securities, Life Science Venture Capital, Marubeni, Mizuho Capital, Nikko antfatory, NIF SMBC Ventures

## Investors

- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series D
- Nomura Securities — Series D
- Life Science Venture Capital (https://capitalatlas.ai/funds/life-science-venture-capital) — Series D
- Marubeni — Series D
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series D
- Nikko antfatory — Series D
- NIF SMBC Ventures (https://capitalatlas.ai/funds/nif-smbc-ventures) — Series D